NCT03923335Not yet recruiting
The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 22 Apr 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate the predictive value of a four-gene methylation assay called Guangzhou Panel in early-stage colorectal cancer. Patients will be divided into two groups: high risk group and low risk group. The primary endpoint is 5 year disease free survival (DFS).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 287 (estimated)
- First submitted
- 14 Apr 2019
- Start date
- 30 Apr 2019
- Primary completion date
- 30 Apr 2021
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Diseases
- Colorectal cancer
- NCT number
- NCT03923335
What you commit to
- Study type: Observational
- Planned participants: 287
- From 30 Apr 2019 to the primary completion date, 30 Apr 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- have had a previous diagnosis of any cancer or presence of any tumor other than the CRC
Other illness
- have had inflammatory bowel disease
- have had hereditary colorectal cancer syndromes, including Familial adenomatous polyposis, mutyh (MYH)-associated polyposis, Peutz-Jeghers syndrome, Juvenile polyposis coli, phosphate and tension homology deleted on chromosome ten (PTEN) tumor-hamartoma syndromes, Lynch Syndrome, and Familial Colorectal Cancer Type X.
Who the study is looking for
- TNM stage I-II (T1-4N0M0) colorectal cancer cases
- receive radical surgical resection
- have completed data of tumor location, histological type, behavioral characteristics or TNM staging
- have tumor specimens and either a valid microsatellite instability (MSI) or immuno-histochemistry (IHC) data
- have valid V-raf murine sarcoma viral oncogene homolog B1 (BRAF), kirsten rat sarcoma viral oncogene (KRAS), CpG island methylator phenotype (CIMP) results
- have at least 4 years of follow-up
- have valid time to local recurrence/metastasis in follow-up
- have clinical/treatment record data and valid preoperative status of intestinal obstruction or perforation (IOP), counts of lymph node removed in surgical resection.
Age in the registry: 40 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Sixth Affiliate Hospital of Sun Yat-Sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.